Quince Therapeutics (QNCX) Income towards Parent Company (2018 - 2026)

Quince Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at $35.9 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 338.94% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at -$12.9 million (up 78.81% YoY), while the FY2025 annual figure was -$63.8 million, down 12.28% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $35.9 million, up from -$19.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was $35.9 million in Q1 2026, with the low at -$27.7 million in Q2 2024.
• The 5-year median for Income towards Parent Company is -$12.3 million (2023), against an average of -$9.9 million.
• The sharpest annual moves came in 2024 and 2026: Income towards Parent Company tumbled 467.52% in 2024, then jumped 338.94% in 2026.
• Quince Therapeutics' Income towards Parent Company stood at -$5.5 million in 2022, then slumped by 60.72% to -$8.9 million in 2023, then tumbled by 40.07% to -$12.5 million in 2024, then sank by 54.78% to -$19.3 million in 2025, then jumped by 286.24% to $35.9 million in 2026.
• Business Quant data shows QNCX's Income towards Parent Company at $35.9 million in Q1 2026, -$19.3 million in Q4 2025, and -$13.4 million in Q3 2025.